A5029279262- Muscle Physiology and Disorders
- Eating Disorders and Behaviors
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Digital Mental Health Interventions
- Mental Health Research Topics
- Adipose Tissue and Metabolism
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Muscle activation and electromyography studies
Centre for Human Drug Research
2022-2023
Leiden University Medical Center
2022
Facioscapulohumeral dystrophy (FSHD) is a progressive muscle disorder leading to significant disability. Currently, FSHD symptom severity assessed by clinical assessments such as the score and Timed Up-and-Go test. These are limited in their ability capture changes continuously full impact of disease on patients' quality life. Real-world data related physical activity, sleep, social behavior could potentially provide additional insight into might be useful assessing treatment effects aspects...
Facioscapulohumeral muscular dystrophy (FSHD) is a progressive neuromuscular disease. Its slow and variable progression makes the development of new treatments highly dependent on validated biomarkers that can quantify disease response to drug interventions.We aimed build tool estimates FSHD clinical severity based behavioral features captured using smartphone remote sensor data. The adoption monitoring tools, such as smartphones wearables, would provide novel opportunity for continuous,...
Abstract Drug development for mood disorders can greatly benefit from the of robust, reliable, and objective biomarkers. The incorporation smartphones wearable devices in clinical trials provide a unique opportunity to monitor behavior non-invasive manner. this study is identify correlations between remotely monitored self-reported assessments objectively measured activities with depression severity often applied trials. 30 unipolar depressed patients 29 age- gender-matched healthy controls...
<sec> <title>BACKGROUND</title> Facioscapulohumeral muscular dystrophy (FSHD) is a progressive neuromuscular disease. Its slow and variable progression makes the development of new treatments highly dependent on validated biomarkers that can quantify disease response to drug interventions. </sec> <title>OBJECTIVE</title> We aimed build tool estimates FSHD clinical severity based behavioral features captured using smartphone remote sensor data. The adoption monitoring tools, such as...